HOWARD HUGHES MEDICAL INSTITUTE reported NVIDIA CORPORATION (NVDA) in 10 quarterly 13F filings from 2025 Q2 through 2026 Q2. Peak portfolio weight reached 14.47% in 2026 Q2. The latest visible filing shows NVDA at 14.47% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was HOWARD HUGHES MEDICAL INSTITUTE's position in NVIDIA CORPORATION, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
NVDA was reported at 14.47% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
As of 2026 Q3 — sorted by position size
These are the practical questions this page is built to answer before you even open the full history table.
HOWARD HUGHES MEDICAL INSTITUTE reported NVDA across 5 quarterly 13F filings, from 2025 Q2 through 2026 Q2.
The largest reported portfolio weight for NVDA was 14.47% in 2026 Q2.
The most recent filing on this page is 2026 Q2, when HOWARD HUGHES MEDICAL INSTITUTE reported 322,105 shares, equal to 14.47% of portfolio, with an estimated market value of $64.4M.
The chart compares HOWARD HUGHES MEDICAL INSTITUTE's quarterly NVDA portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.
Based on 13F filing dates vs. subsequent NVDA price moves, HOWARD HUGHES MEDICAL INSTITUTE correctly timed 3 out of 5 reported position changes (60%). The annualised alpha on NVDA relative to SPY over the holding period was +2076.2%.